title: The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration.
authors.affiliation: rsteinbrook@attglobal.net
authors.forename: Robert
authors.initials: R
authors.lastname: Steinbrook
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000191:economics; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy*; D000069579:Ranibizumab
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab